---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-015262"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:43:07.891228+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics raises $1M in private placement at $0.60 per share

## Summary
- Entered Securities Purchase Agreement for $1M total, closings of $500k each on Feb 9, 2026 and ~30 days later.
- Investor receives common stock or pre-funded warrants at $0.60 and common warrants for 120% of shares at $1.00 exercise price.
- First closing occurred on February 9, 2026; second closing subject to conditions.
- Net proceeds for working capital; registration statement to be filed within 45 days.
- Issuance exempt under Section 4(a)(2) and Regulation D; OTCQB ticker BCLI.

## SEC filing metadata
- accession: 0001104659-26-015262
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926015262/0001104659-26-015262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926015262/tm266260d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-015262
- JSON: https://secwatch.observer/filing/0001104659-26-015262.json
- Plain text: https://secwatch.observer/filing/0001104659-26-015262.txt

## Source-grounded claims
- claim_id: ed4a07d79c115bb20bcb1a874cc39645e2f687a8
  claim: BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with an accredited investor valued at $1,000,000 (effective 2026-02-09).
  evidence_excerpt: On February 9, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926015262/0001104659-26-015262-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.